Financial - Conglomerates
Build Your Comparison
Side-by-side financial analysisStock Comparison
ACOG vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ACOG vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Financial - Conglomerates | Biotechnology |
| Market Cap | $98M | $7.70B |
| Revenue (TTM) | $11M | $0.00 |
| Net Income (TTM) | $-25M | $-327M |
| Gross Margin | 86.4% | — |
| Operating Margin | -250.1% | — |
| Total Debt | $0.00 | $110K |
| Cash & Equiv. | $66M | $357M |
ACOG vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | Jun 26 | Return |
|---|---|---|---|
| Alpha Cognition Inc… (ACOG) | 100 | 95.2 | -4.8% |
| Praxis Precision Me… (PRAX) | 100 | 332.5 | +232.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACOG vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACOG is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.29
- EPS growth 42.1%
- -11.3% 10Y total return vs PRAX's -36.1%
PRAX carries the broadest edge in this set and is the clearest fit for growth and quality.
- -100.0% revenue growth vs ACOG's -116.5%
- 2.4% margin vs ACOG's -232.2%
- +491.9% vs ACOG's -34.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -100.0% revenue growth vs ACOG's -116.5% | |
| Quality / Margins | 2.4% margin vs ACOG's -232.2% | |
| Stability / Safety | Beta 1.29 vs PRAX's 1.55 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +491.9% vs ACOG's -34.4% | |
| Efficiency (ROA) | -40.2% ROA vs ACOG's -41.8%, ROIC -65.0% vs -32.4% |
ACOG vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ACOG vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PRAX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACOG and PRAX operate at a comparable scale, with $11M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $11M | $0 |
| EBITDAEarnings before interest/tax | -$27M | -$357M |
| Net IncomeAfter-tax profit | -$25M | -$327M |
| Free Cash FlowCash after capex | -$30M | -$283M |
| Gross MarginGross profit ÷ Revenue | +86.4% | — |
| Operating MarginEBIT ÷ Revenue | -2.5% | — |
| Net MarginNet income ÷ Revenue | -2.3% | — |
| FCF MarginFCF ÷ Revenue | -2.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -146.2% | +2.7% |
Valuation Metrics
Evenly matched — ACOG and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $98M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $32M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.38x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.57x | — |
| Price / BookPrice ÷ Book value/share | 1.78x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ACOG leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-54 for ACOG. On the Piotroski fundamental quality scale (0–9), ACOG scores 4/9 vs PRAX's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -54.1% | -43.0% |
| ROA (TTM)Return on assets | -41.8% | -40.2% |
| ROICReturn on invested capital | -32.4% | -65.0% |
| ROCEReturn on capital employed | -38.4% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$66M | -$357M |
| Cash & Equiv.Liquid assets | $66M | $357M |
| Total DebtShort + long-term debt | $0 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
Evenly matched — ACOG and PRAX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACOG five years ago would be worth $8,873 today (with dividends reinvested), compared to $8,580 for PRAX. Over the past 12 months, PRAX leads with a +491.9% total return vs ACOG's -34.4%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs ACOG's -3.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -3.1% | -6.9% |
| 1-Year ReturnPast 12 months | -34.4% | +491.9% |
| 3-Year ReturnCumulative with dividends | -11.3% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -11.3% | -14.2% |
| 10-Year ReturnCumulative with dividends | -11.3% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -3.9% | +164.8% |
Risk & Volatility
Evenly matched — ACOG and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACOG is the less volatile stock with a 1.29 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs ACOG's 54.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.55x |
| 52-Week HighHighest price in past year | $11.54 | $366.52 |
| 52-Week LowLowest price in past year | $4.50 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +54.6% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 42K | 396K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ACOG as "Buy" and PRAX as "Buy". Consensus price targets imply 127.8% upside for PRAX (target: $607) vs 122.2% for ACOG (target: $14).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $607.15 |
| # AnalystsCovering analysts | 1 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRAX leads in 1 of 6 categories (Income & Cash Flow). ACOG leads in 1 (Profitability & Efficiency). 3 tied.
ACOG vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ACOG or PRAX a better buy right now?
Analysts rate Alpha Cognition Inc.
Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACOG or PRAX?
Over the past 5 years, Alpha Cognition Inc.
Common Stock (ACOG) delivered a total return of -11. 3%, compared to -14. 2% for Praxis Precision Medicines, Inc. (PRAX). Over 10 years, the gap is even starker: ACOG returned -11. 3% versus PRAX's -36. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACOG or PRAX?
By beta (market sensitivity over 5 years), Alpha Cognition Inc.
Common Stock (ACOG) is the lower-risk stock at 1. 29β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 21% more volatile than ACOG relative to the S&P 500.
04Which is growing faster — ACOG or PRAX?
On earnings-per-share growth, the picture is similar: Alpha Cognition Inc.
Common Stock grew EPS 42. 1% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACOG or PRAX?
Praxis Precision Medicines, Inc.
(PRAX) is the more profitable company, earning 0. 0% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAX leads at 0. 0% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — ACOG leads at 81. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ACOG or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ACOG or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Alpha Cognition Inc.
Common Stock (ACOG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29)). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACOG: -11. 3%, PRAX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ACOG and PRAX?
These companies operate in different sectors (ACOG (Financial Services) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.